Cellosaurus logo
expasy logo
Due to maintenance work, this service will be unavailable from Mon Nov 11 17:30 until Tue Nov 12 09:00 CET. Apologies for the inconvenience.

Cellosaurus LN229/HER2 (CVCL_D2T3)

[Text version]
Cell line name LN229/HER2
Accession CVCL_D2T3
Resource Identification Initiative To cite this cell line use: LN229/HER2 (RRID:CVCL_D2T3)
Comments Population: Caucasian.
Genetic integration: Method=Transfection/transduction; Gene=HGNC; 3430; ERBB2 (Note=With a N-terminal GVAMPGAEDDVV = PA-tag and a C-terminal DMVNPGLEDRIE = RAP-tag and GDGMVPPGIEDK = MAP-tag).
Derived from site: In situ; Brain, right frontal parieto-occipital cortex.
Sequence variations
  • Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line).
Disease Glioblastoma (NCIt: C3058)
Glioblastoma (ORDO: Orphanet_360)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0393 (LN-229)
Sex of cell Female
Age at sampling 60Y
Category Cancer cell line
Publications

PubMed=28700270; DOI=10.1089/mab.2017.0026; PMCID=PMC6985780
Itai S., Fujii Y., Kaneko M.K., Yamada S., Nakamura T., Yanaka M., Saidoh N., Chang Y.-W., Handa S., Takahashi M., Suzuki H., Harada H., Kato Y.
H2Mab-77 is a sensitive and specific anti-HER2 monoclonal antibody against breast cancer.
Monoclon. Antib. Immunodiagn. Immunother. 36:143-148(2017)

PubMed=29172998; DOI=10.1089/mab.2017.0050
Yamada S., Itai S., Nakamura T., Chang Y.-W., Harada H., Suzuki H., Kaneko M.K., Kato Y.
Establishment of H2Mab-119, an anti-human epidermal growth factor receptor 2 monoclonal antibody, against pancreatic cancer.
Monoclon. Antib. Immunodiagn. Immunother. 36:287-290(2017)

PubMed=29315012; DOI=10.1089/mab.2017.0052
Kaneko M.K., Yamada S., Itai S., Kato Y.
Development of an anti-HER2 monoclonal antibody H2Mab-139 against colon cancer.
Monoclon. Antib. Immunodiagn. Immunother. 37:59-62(2018)

PubMed=31199696; DOI=10.1089/mab.2019.0017
Kato Y., Ohishi T., Yamada S., Itai S., Takei J., Sano M., Nakamura T., Harada H., Kawada M., Kaneko M.K.
Anti-human epidermal growth factor receptor 2 monoclonal antibody H2Mab-41 exerts antitumor activity in a mouse xenograft model of colon cancer.
Monoclon. Antib. Immunodiagn. Immunother. 38:157-161(2019)

PubMed=32765652; DOI=10.3892/etm.2020.8765; PMCID=PMC7388441
Takei J., Kaneko M.K., Ohishi T., Kawada M., Harada H., Kato Y.
H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts.
Exp. Ther. Med. 20:846-853(2020)

PubMed=34424764; DOI=10.1089/mab.2021.0021
Takei J., Asano T., Tanaka T., Sano M., Hosono H., Nanamiya R., Tateyama N., Saito M., Suzuki H., Harada H., Kaneko M.K., Kato Y.
Development of a novel anti-HER2 monoclonal antibody H2Mab-181 for gastric cancer.
Monoclon. Antib. Immunodiagn. Immunother. 40:168-176(2021)

Cross-references
Encyclopedic resources Wikidata; Q127382605
Entry history
Entry creation30-Jan-2024
Last entry update10-Sep-2024
Version number2